Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a...

Area of Science:

• Paediatric Oncology
• Hematology
• Leukemia Research

Background:

• Early T-precursor acute lymphoblastic leukaemia (ETP-ALL) is a distinct subtype of T-cell acute lymphoblastic leukaemia (T-ALL).
• ETP-ALL has been associated with a poorer prognosis in previous studies.
• Understanding the outcomes for ETP-ALL patients treated on contemporary protocols is crucial for refining treatment strategies.

Purpose of the Study:

• To evaluate the clinical outcomes of children and young people diagnosed with ETP-ALL.
• To compare the outcomes of ETP-ALL patients with those of typical T-ALL patients.
• To determine if ETP-ALL warrants universal experimental treatment or allogeneic stem cell transplantation in first remission.

Main Methods:

• Retrospective analysis of patients treated on the UKALL 2003 protocol.
• Comparison of event-free survival (EFS) and overall survival (OS) between ETP-ALL and typical T-ALL subgroups.
• Analysis of relapse rates in ETP-ALL patients.

Main Results:

• The ETP-ALL subgroup represented 16% of T-ALL patients in the study cohort.
• After a median follow-up of 4 years and 10 months, ETP-ALL patients showed non-significantly inferior 5-year EFS (76.7% vs. 84.6%, P=0.2) and OS (82.4% vs. 90.9%, P=0.1).
• ETP-ALL patients had a higher relapse rate (18.6% vs. 9.6%, P=0.1) compared to typical T-ALL.

Conclusions:

• ETP-ALL exhibits an intermediate risk outcome, rather than a universally poor prognosis.
• The current data do not support the universal application of experimental treatments for all ETP-ALL patients.
• Universal allogeneic transplantation in first remission is not indicated for the ETP-ALL group based on these findings.